Comparable effect of empagliflozin and dapagliflozin therapy on the dynamics of markers of hepatic fibrosis at patients with type 2 diabetes mellitus

Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease worldwide, especially in patients with type 2 diabetes mellitus and obesity. Thirty-four patients with NAFLD were enrolled and administered empagliflozin 10 mg or dapagliflozin 10 mg once a day. Body weight and serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), triglycerides (TG), glycated haemoglobin (HbA1C) decreased significantly after 24 weeks of empagliflozin and dapagliflozin treatment. The ALT level decreased from 41.6±8.6 to 26.8±8.3 u/l (p=0.002), the AST level decreased from 35.3±6.8 to 21.9±7.1 U/l (p=0.0029). The risk of fibrosis was mild and reached statistical significance only when assessed with FIB-4 index, when comparing the initial values and after 24 weeks of treatment - 1.35±0.48 and 1.15±0.35, respectively (p=0.025). This fact can be explained by the minimal degree of fibrosis at the baseline. Conclusion. There were comparable effects of empagliflozin and dapagliflozin on estimated parameters at the end of the study. Further studies on big cohorts of patients with different stages of NAFLD are required to unambiguously answer the question about the effect of iSGLT2 on the progress of this disease.

сахарный диабет 2 типа, ожирение, галектин-3, маркеры фиброза, ингибиторы глюкозо-натриевого ко-транспортера 2 типа, Non-alcoholic fatty liver disease, type 2 diabetes mellitus, galectin-3, markers of fibrosis, obesity, sodium-glucose co-transporter 2 inhibitors, неалкогольная жировая болезнь печени